Came up 0 results for me banker on PSTI site, but did scope this - he's at bottom fairly recent.

Pluristem Therapeutics Inc.

TICKER: PSTI:NASDAQ

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Jason Kolbert, Maxim Group (1/23/14) "We toured Pluristem Therapeutics Inc.'s new manufacturing facility. . .we were impressed with the level and scope of activity in this fully occupied and operational state-of-the-art facility. We believe that the company's manufacturing position is likely to translate into a key competitive advantage (this facility can produce 150,000 'doses') as clinical trials advance and ultimately as Pluristem competes in the space with its 100%-owned and -controlled commercial-scale facility."

Jason Kolbert, Maxim Group (1/21/14) "Pluristem Therapeutics Inc. is advancing placental expanded cells (PLX) on multiple fronts. In addition to the trial for muscle injury, we expect the company to see PLX enter the clinic this year in pre-eclampsia."

The Life Sciences Report Interview with Jason Kolbert (12/19/13) "I think a major paradigm shift is going to be led by those companies that have good balance sheets. . .it will also be led by companies that have partners with viable business models. Pluristem has a great partner in United Therapeutics Corp." More >

Eun Yang, Jefferies & Co. (11/21/13) "With partner CHA Bio & Diostech Ltd. primarily developing placental-derived adherent stromal cell (PLX-PAD), Pluristem Therapeutics Inc. is to focus on PLacental eXpanded (PLX) development in preeclampsia. Pending FDA approval of commercial-grade production of PLX (expected in January/February 2014), CHA Bio is to start phase 2/3 in critical limb ischemia and phase 2 in intermittent claudication in H1/14. In addition, Pluristem plans to start phase 1/2 in preeclampsia. Now we expect data from these studies in 2015. . .with ~$49M cash at the end of Q3/13 and ~$20M annual cash burn, Pluristem has enough cash for ~2 years."

George Zavoico, MLV & Co (11/5/13) "Yesterday, Pluristem Therapeutics Inc. announced positive results of a preclinical animal maternal and fetal toxicity study of its PLacental eXpanded (PLX) cells. . .as a fairly common unmet clinical need with potentially lethal outcomes, we think PLX cells for preeclampsia could be granted breakthrough therapy designation. These positive safety results could lead to the start of a clinical trial in H1/14 and marketing approval in 2017, in a bull case scenario. We reiterate our Buy recommendation and $4.50 one-year price target."